PYXS (Pyxis Oncology) EBIT per Share : $-1.23 (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pyxis Oncology EBIT per Share?

Pyxis Oncology's EBIT per Share for the three months ended in Sep. 2024 was $-0.39. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.23.

During the past 3 years, the average EBIT per Share Growth Rate was -52.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Pyxis Oncology's EBIT per Share or its related term are showing as below:

PYXS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -205.6 Med: -128.95 Max: -52.3
Current: -52.3

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Pyxis Oncology was -52.30% per year. The lowest was -205.60% per year. And the median was -128.95% per year.

PYXS's 3-Year EBIT Growth Rate is ranked worse than
90.06% of 1248 companies
in the Biotechnology industry
Industry Median: 2.8 vs PYXS: -52.30

Pyxis Oncology's EBIT for the three months ended in Sep. 2024 was $-23.75 Mil.

Pyxis Oncology EBIT per Share Historical Data

The historical data trend for Pyxis Oncology's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pyxis Oncology EBIT per Share Chart

Pyxis Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.13

-0.58

-8.21

-3.74

-2.06

Pyxis Oncology Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial														-0.61	-0.40	-0.11	-0.33	-0.39

Pyxis Oncology EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Pyxis Oncology's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-82.196	/	39.905
=	-2.06

Pyxis Oncology's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-23.754	/	60.715
=	-0.39

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.23

Pyxis Oncology (NAS:PYXS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Pyxis Oncology EBIT per Share Related Terms

Thank you for viewing the detailed overview of Pyxis Oncology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Pyxis Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pyxis Oncology Inc (NAS:PYXS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Harrison Avenue, Boston, MA, USA, 02118

Website

https://www.pyxisoncology.com

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Executives

Pamela Ann Connealy	officer: Chief Financial Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jitendra Wadhane	officer: Chief Accounting Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lara Sullivan	director, officer: Chief Executive Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jakob Dupont	director	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Pfizer Inc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Pfizer Ventures (us) Llc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Rachel Humphrey	director	C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Mark Chin	other: Former Director	20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ
Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Thomas Civik	director	C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bayer World Investments B.v.	10 percent owner	ENERGIEWEG 1, MIJDRECHT P7 3641
Freda C Lewis-hall	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ronald Herbst	officer: Chief Scientific Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140